#United States #Raleigh #RedHill Biopharma #Rebyota #Clenpiq

RedHill's Strategic Acquisition of Ferring's Rebyota® and Clenpiq®

On September 1, 2026, RedHill Biopharma Ltd., a distinguished biopharmaceutical entity, announced a pivotal moment in its expansion strategy: the acquisition of exclusive global and U.S. commercialization rights to Ferring Pharmaceuticals' gastrointestinal (GI) drugs, Rebyota® and Clenpiq®. This transformative move, coupled with the recent divestiture of Talicia®, positions RedHill to enhance its portfolio and strengthen its foothold in the GI market.

A New Era for RedHill's GI Business

The completion of this acquisition signifies a major shift for RedHill's GI operations, as it transitions into a more substantial, revenue-generating entity in this specialty area. Both Rebyota and Clenpiq are well-established FDA-approved medications that generated combined net sales of approximately $37.5 million in the U.S. in 2025. This acquisition not only diversifies RedHill’s offerings but also enhances its liquidity and offers potential growth avenues amid an increasingly competitive landscape.

Dror Ben-Asher, CEO of RedHill, remarked on the thoughtful execution of this strategic sequence. The company first monetized Talicia for $18 million, leveraging this capital to secure the proprietary rights to these valuable products. He believes that the integration of Rebyota and Clenpiq into their portfolio will contribute positively to RedHill’s cash flow, facilitating further growth initiatives in the future.

Understanding Rebyota® and Clenpiq®

Rebyota®

Rebyota is the first FDA-approved single-dose Fecal Microbiota Transplant (FMT) therapy dedicated to preventing recurrent Clostridioides difficile infections (rCDI). Officially introduced in 2022 and subsequently endorsed by Health Canada in 2025, it has quickly established itself as a critical option for treating rCDI patients. Rebyota has performed impressively, boasting over a 70% success rate in preventing rCDI with just a single administration, an attractive feature for both patients and healthcare providers.

The significance of Rebyota in combating CDI, a condition that affects approximately 500,000 individuals in the U.S. yearly, cannot be overstated. With 30,000 deaths attributed to CDI annually in the U.S. and a substantial rise in aged population susceptibility, Rebyota addresses a significant health challenge.

Clenpiq®

Clenpiq is characterized as a low-volume bowel preparation solution, designed specifically for colon cleansing prior to procedures such as colonoscopies. With a straightforward administration method requiring no mixing, Clenpiq generated approximately $20.6 million in U.S. net sales in 2025 with minimal promotional efforts. Its ease of use and comprehensive coverage options make it a compelling choice for healthcare providers and patients alike.

A Growth Catalyst

The acquisition of Rebyota and Clenpiq serves as a catalytic force for both immediate and long-term commercial growth for RedHill. With comprehensive market strategies and an experienced team already in place, RedHill is prepared to expand the reach of these products not just in the U.S., but also in other intended markets. The deal positions RedHill more favorably as it navigates the complexities of the pharmaceutical landscape, particularly in light of the company’s plans to identify and integrate other revenue-generating products in the future.

In conclusion, RedHill’s strategic acquisition not only represents a significant shift in its operational capabilities but also opens new avenues for innovation in the GI sector. By leveraging the established presence of Rebyota and Clenpiq, RedHill is poised for enhanced market penetration and sustained growth as it works towards its goal of operational profitability.